Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ASP Isotopes Inc. Common Stock (ASPI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: ASPI (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 486.59% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 664.21M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 1 | Beta 3.59 | 52 Weeks Range 1.86 - 10.08 | Updated Date 07/11/2025 |
52 Weeks Range 1.86 - 10.08 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -721.89% |
Management Effectiveness
Return on Assets (TTM) -26.14% | Return on Equity (TTM) -115.46% |
Valuation
Trailing PE - | Forward PE 54.35 | Enterprise Value 568772077 | Price to Sales(TTM) 150.77 |
Enterprise Value 568772077 | Price to Sales(TTM) 150.77 | ||
Enterprise Value to Revenue 129.11 | Enterprise Value to EBITDA -12.17 | Shares Outstanding 83875400 | Shares Floating 48604044 |
Shares Outstanding 83875400 | Shares Floating 48604044 | ||
Percent Insiders 27.05 | Percent Institutions 43.84 |
Upturn AI SWOT
ASP Isotopes Inc. Common Stock
Company Overview
History and Background
ASP Isotopes Inc., founded in 2012, focuses on the development and production of enriched isotopes for various industries. It aims to be a leading supplier of isotopes for medical, industrial, and research applications.
Core Business Areas
- Isotope Production: Production and enrichment of various isotopes, including enriched uranium, for use in medical imaging, industrial gauging, and scientific research.
- Manufacturing of isotope based products: Design, manufacture, and sales of radiation sources that utilize enriched radioisotopes
Leadership and Structure
The company is led by a management team with expertise in isotope enrichment and commercialization. Its organizational structure includes departments for research and development, production, sales, and finance.
Top Products and Market Share
Key Offerings
- Enriched Uranium: ASP Isotopes focuses on enriched uranium, particularly U-235 for various industrial and medical uses. Exact market share data is difficult to find but the demand for high assay low enriched uranium is expected to grow considerably with the build out of small modular nuclear reactors and medical isotopes. Competitors for enriched uranium include Centrus Energy (LEU) and Orano.
- Medical Isotopes: Production of isotopes used in medical imaging and therapy, contributing to diagnostics and treatment of diseases. They are also developing the production of actinium-225, a radiotherapy medical isotope. Competitors for actinium-225 include ITM Isotope Technologies Munich SE.
Market Dynamics
Industry Overview
The isotope market is growing, driven by increasing demand in medical, industrial, and research sectors. Specific enriched isotope requirements are increasing due to increased application.
Positioning
ASP Isotopes positions itself as a key supplier of enriched isotopes, focusing on high-quality production and customization for specific applications. The company aims to secure a strong position in the burgeoning market for High-Assay Low-Enriched Uranium (HALEU).
Total Addressable Market (TAM)
The TAM for isotopes is estimated to be several billion dollars annually and is growing. ASP Isotopes aims to capture a significant share by focusing on niche markets and specialized isotope products and offering supply to the small modular reactor industry.
Upturn SWOT Analysis
Strengths
- Expertise in isotope enrichment
- Proprietary enrichment technology
- Focus on high-purity isotopes
- Strategic partnerships with industry leaders
- Growing demand for isotopes in medical and industrial applications
Weaknesses
- Small Market Capitalization
- Limited operational history as a public company
- Dependence on government approvals and regulations
- Capital-intensive operations
- Reliance on securing contracts and funding for expansion
Opportunities
- Expansion into new isotope markets
- Development of innovative isotope applications
- Strategic acquisitions to expand capabilities
- Increased government funding for isotope research and production
- Partnerships with medical and industrial companies
Threats
- Competition from established isotope suppliers
- Fluctuations in isotope prices
- Changes in government regulations
- Technological advancements that could render existing enrichment methods obsolete
- Disruptions in the supply chain for raw materials
Competitors and Market Share
Key Competitors
- LEU
- CCJ
- UUUU
Competitive Landscape
ASP Isotopes faces competition from larger, more established companies. Its competitive advantage lies in its proprietary technology and focus on specialized isotope applications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's relatively recent listing.
Future Projections: Future growth projections depend on successful expansion into new markets and obtaining key contracts.
Recent Initiatives: Recent initiatives include forming strategic partnerships and developing advanced isotope enrichment technologies.
Summary
ASP Isotopes is a developing company in the isotope production market, showing promise with its technology and focus on enriched uranium and medical isotopes. While it faces significant competition and financial constraints, strategic partnerships and expanding into new applications could drive future growth. Investors should monitor the company's progress in securing contracts, navigating regulations, and managing its capital-intensive operations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Analyst Research
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ASP Isotopes Inc. Common Stock
Exchange NASDAQ | Headquaters Washington, DC, United States | ||
IPO Launch date 2022-11-10 | President, CEO & Executive Chairman Mr. Paul Elliot Mann C.F.A. | ||
Sector Basic Materials | Industry Chemicals | Full time employees 136 | Website https://aspisotopes.com |
Full time employees 136 | Website https://aspisotopes.com | ||
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes. It operates in two segments, Nuclear Fuels and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which selectively ionizes and separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry; Silicon-28, which is used in semiconductors; and Carbon-14 for pharmaceuticals and agrochemicals. In addition, the company develops Zinc-67/68, Nickel-68, and Xenon 129/136 for the nuclear medical industry; Lithium-6, Lithium-7, Uranium-235, Chlorine-37, and Thorium Fluoride for the energy industry; and Germanium-70/72/74. ASP Isotopes Inc. was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.